Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Double-S Clear all
Not listed Phase 3 Interventional Accepts healthy volunteers

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

NCT05293665
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine, Sinopharm BIBP
Biological
Lead sponsor
Vaxxinity, Inc.
Industry
Eligibility
16 Years and older
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brownsville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 4 Interventional

A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)

NCT00321152
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
6(S)-5-MTHF (a Medical Food)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
11
States / cities
San Diego, California • Chicago, Illinois • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2010 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease

NCT00851981
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Placebo, SAMe
Other · Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749904
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Cook Balloon vs Dilapan-S for Outpatient Cervical Ripening

NCT05062343
View directory record Official record
Conditions
Induced; Birth
Interventions
Dilapan-S, Cook Cervical Ripening Balloon
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

NCT01971515
View directory record Official record
Conditions
Solid Tumor
Interventions
MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Pilot Study to Improve Care Coordination

NCT02386189
View directory record Official record
Conditions
Chronic Illness
Interventions
Patient Care Coordination Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers

NCT00663091
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Bacteriophage, WPP-201 Bacteriophage, Bacteriophages
Drug
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 29, 2026, 4:14 PM EDT
Withdrawn Not applicable Interventional

Intraoperative Imaging of a PET Positive Lymph Node(s) Using 18FDG and a Dual-Mode, Hand-Held Intraoperative Imager

NCT03561324
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Imaging Beta Probe (IBP)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

NCT03416179
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
glasdegib, daunorubicin + cytarabine, azacitidine, Placebo, cytarabine, HSCT
Drug · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
16
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 29, 2026, 4:14 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

NCT06964230
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T3D-959, Placebo Comparator
Drug · Other
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 29, 2026, 4:14 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study

NCT01376765
View directory record Official record
Conditions
SARS
Interventions
Aluminum hydroxide adjuvant (Alhydrogel®), Phosphate buffered saline Placebo, Recombinant S protein SARS vaccine
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
3
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold

NCT02550093
View directory record Official record
Conditions
Healthy
Interventions
Intervention 1, Washout Period, Intervention 2
Procedure · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
20 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT01004978
View directory record Official record
Conditions
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Interventions
Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
281
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee

NCT01887678
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Traumeel® / Zeel® Injectable Solution, Placebo
Drug
Lead sponsor
Biologische Heilmittel Heel GmbH
Industry
Eligibility
45 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Dinuba, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 29, 2026, 4:14 PM EDT
Completed No phase listed Observational

Sensing Atrial High Rate Episodes With Implantable Cardioverter-Defibrillators Trial (The SENSE Trial)

NCT02186704
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
ICD with DX system
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Yellow Fever Virus Vaccine and Immune Globulin Study

NCT00254826
View directory record Official record
Conditions
Viremia
Interventions
YF-VAX® plus saline, 17D YF Vaccine plus Ig,
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 29, 2026, 4:14 PM EDT
Not listed No phase listed Observational

Multidimensional Classification of Mild Traumatic Brain Injury (mTBI)

NCT04874389
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Multimodal Assessment
Diagnostic Test
Lead sponsor
Clea Tucker
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

NCT02788188
View directory record Official record
Conditions
Middle East Respiratory Syndrome Coronavirus
Interventions
SAB-301, Normal (9%) Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

NCT00919503
View directory record Official record
Conditions
Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions
Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
Procedure · Biological · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 29, 2026, 4:14 PM EDT
Recruiting Phase 3 Interventional

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135
View directory record Official record
Conditions
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Interventions
Navtemadlin, Navtemadlin placebo, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
58
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia

NCT01670825
View directory record Official record
Conditions
Occipital Neuralgia
Interventions
Pulsed radiofrequency, Corticosteroid injection, Local anethestic injection
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 29, 2026, 4:14 PM EDT